Ecological Assessment of Clinicians’ Antipsychotic Prescription Habits in Psychiatric Inpatients: A Novel Web- and Mobile Phone–Based Prototype for a Dynamic Clinical Decision Support System

Background Electronic prescribing devices with clinical decision support systems (CDSSs) hold the potential to significantly improve pharmacological treatment management. Objective The aim of our study was to develop a novel Web- and mobile phone–based application to provide a dynamic CDSS by monitoring and analyzing practitioners’ antipsychotic prescription habits and simultaneously linking these data to inpatients’ symptom changes. Methods We recruited 353 psychiatric inpatients whose symptom levels and prescribed medications were inputted into the MEmind application. We standardized all medications in the MEmind database using the Anatomical Therapeutic Chemical (ATC) classification system and the defined daily dose (DDD). For each patient, MEmind calculated an average for the daily dose prescribed for antipsychotics (using the N05A ATC code), prescribed daily dose (PDD), and the PDD to DDD ratio. Results MEmind results found that antipsychotics were used by 61.5% (217/353) of inpatients, with the largest proportion being patients with schizophrenia spectrum disorders (33.4%, 118/353). Of the 217 patients, 137 (63.2%, 137/217) were administered pharmacological monotherapy and 80 (36.8%, 80/217) were administered polytherapy. Antipsychotics were used mostly in schizophrenia spectrum and related psychotic disorders, but they were also prescribed in other nonpsychotic diagnoses. Notably, we observed polypharmacy going against current antipsychotics guidelines. Conclusions MEmind data indicated that antipsychotic polypharmacy and off-label use in inpatient units is commonly practiced. MEmind holds the potential to create a dynamic CDSS that provides real-time tracking of prescription practices and symptom change. Such feedback can help practitioners determine a maximally therapeutic drug treatment while avoiding unproductive overprescription and off-label use.

[1]  C. Haw,et al.  Off-label use of antipsychotics: are we mad? , 2007, Expert opinion on drug safety.

[2]  P. Rompré,et al.  Antipsychotic Agents for the Treatment of Substance Use Disorders in Patients With and Without Comorbid Psychosis , 2010, Journal of clinical psychopharmacology.

[3]  Joy L. Johnson,et al.  Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. , 2010, The Journal of clinical psychiatry.

[4]  U. Lertxundi,et al.  Antipsychotic polypharmacy: a needle in a haystack? , 2012, General hospital psychiatry.

[5]  Sowmya R. Rao,et al.  Electronic health records in ambulatory care--a national survey of physicians. , 2008, The New England journal of medicine.

[6]  Leo Anthony Celi,et al.  Dynamic Clinical Data Mining: Search Engine-Based Decision Support , 2014, JMIR medical informatics.

[7]  George Hripcsak,et al.  Caveats for the use of operational electronic health record data in comparative effectiveness research. , 2013, Medical care.

[8]  Åke Grönlund,et al.  Mobile Technologies and Geographic Information Systems to Improve Health Care Systems: A Literature Review , 2014, JMIR mHealth and uHealth.

[9]  F. Zitman,et al.  Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness , 2013, Journal of psychopharmacology.

[10]  C. Correll,et al.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice. , 2012, The Psychiatric clinics of North America.

[11]  David W Bates,et al.  Can electronic clinical documentation help prevent diagnostic errors? , 2010, The New England journal of medicine.

[12]  Anne F. Kittler,et al.  A cost-benefit analysis of electronic medical records in primary care. , 2003, The American journal of medicine.

[13]  B. Wright,et al.  Augmentation with Atypical Antipsychotics for Depression: A Review of Evidence‐Based Support from the Medical Literature , 2013, Pharmacotherapy.

[14]  Patricia M. L. A. van den Bemt,et al.  Research Paper: The Influence that Electronic Prescribing Has on Medication Errors and Preventable Adverse Drug Events: an Interrupted Time-series Study , 2009, J. Am. Medical Informatics Assoc..

[15]  S. Stahl,et al.  A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. , 2004, Current medicinal chemistry.

[16]  S. Stahl Emerging guidelines for the use of antipsychotic polypharmacy. , 2013, Revista de psiquiatria y salud mental.

[17]  David Taylor,et al.  Factors associated with non evidence-based prescribing of antipsychotics , 2014, Therapeutic advances in psychopharmacology.

[18]  E. Vilella,et al.  A Non-Interventional Naturalistic Study of the Prescription Patterns of Antipsychotics in Patients with Schizophrenia from the Spanish Province of Tarragona , 2015, PLoS ONE.

[19]  F. Mayoral,et al.  [Analysis of prescription patterns of antipsychotic agents in psychiatry]. , 2006, Actas espanolas de psiquiatria.

[20]  Igor Jurisica,et al.  Knowledge Discovery and interactive Data Mining in Bioinformatics - State-of-the-Art, future challenges and research directions , 2014, BMC Bioinformatics.

[21]  Mark Erik Larsen,et al.  Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality , 2015, Journal of medical Internet research.

[22]  Leo Anthony Celi,et al.  Disrupting Electronic Health Records Systems: The Next Generation , 2015, JMIR medical informatics.

[23]  Søren Brunak,et al.  Compass: A hybrid method for clinical and biobank data mining , 2014, J. Biomed. Informatics.

[24]  Byron Havard,et al.  Mental Health Mobile Apps: From Infusion to Diffusion in the Mental Health Social System , 2015, JMIR mental health.

[25]  W. Fleischhacker,et al.  Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. , 2014, The international journal of neuropsychopharmacology.

[26]  M. Linden,et al.  Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study , 2004, Human psychopharmacology.

[27]  S. Kapur,et al.  Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. , 2000, The American journal of psychiatry.

[28]  J. Calabrese,et al.  Balancing benefits and harms of treatments for acute bipolar depression. , 2014, Journal of affective disorders.